New York-based global type 1 diabetes (T1D) research and advocacy organisation Breakthrough T1D and the Walgreens Foundation announced on Thursday a new national partnership supporting Breakthrough T1D's mission and advancing the Walgreens Foundation's 'Care for Every Community' platform.
Together, the organisations say that they will help ensure that the 1 in 31 families impacted by T1D in the United States are healthy today for the cures of tomorrow.
Through a USD1 million direct cash commitment over three years, the Walgreens Foundation says that it will support Breakthrough T1D and the T1D community by delivering trusted resources and community support and helping accelerate research toward T1D cures. Beyond this direct commitment, the Walgreens Foundation aims to raise USD15m over three years for Breakthrough T1D through checkout fundraising campaigns in Walgreens stores, with the first campaign launching in May 2027.
Through this partnership, the Walgreens Foundation adds that it will support community awareness, education, and engagement programs focused on T1D, early detection, and clinical trials, and pharmacists will receive access to ACPE-accredited continuing education activities that will help strengthen care for those living with T1D. In May 2027, Walgreens stores will launch the first of these checkout campaigns, raising important funds for Breakthrough T1D and T1D research and giving customers an easy way to support the T1D community by making a voluntary donation at checkout.
Aroa Biosurgery reports significantly improved healing of diabetic foot ulcers in Symphony trial
Lilly reports positive 48-week Phase 2b resu;ts for EloraTZP
Revvity launches IVDR-certified solution for early detection of type 1 diabetes
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Ascletis Pharma Inc doses first participant in global Phase III clinical programme of ASC30
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
Nippon Kinzoku begins mass production of ultra-thin stainless steel for insulin needles
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
Annexin Pharmaceuticals receives proposed INN vanexin for ANXV